Global medical technology company Convatec has announced plans to establish a new flagship research and development hub in Manchester as part of a £500 million investment in the United Kingdom. The FTSE100-listed firm, which specializes in products for chronic wounds, diabetes, urinary incontinence, and stomas, will relocate its R&D operations from Deeside to Bruntwood SciTech's CityLabs 4.0 facility, scheduled to open in 2027. This strategic move represents a significant commitment to the UK's life sciences sector at a time when several other pharmaceutical companies have been shifting investments overseas.

The new Manchester facility will become one of the largest centers in Convatec's global network, spanning 125,000 square feet across seven storeys in the £42 million CityLabs 4.0 building. Located on Hathersage Road facing the Manchester Royal Infirmary, St Mary's and Royal Manchester Children's Hospital, the state-of-the-art facility will focus on research in four key therapeutic areas: advanced wound care, ostomy care, continence care, and infusion care. The company cited Manchester's "vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions" as the primary reason for selecting the location.

Approximately 200 staff will be employed at the new Manchester hub, with most positions transferring from Convatec's existing R&D operation in Deeside, North Wales, which has served as a major research center since 1996. The company emphasized that no redundancies are planned as a consequence of the relocation and that the Deeside manufacturing site will remain unaffected, continuing to employ around 400 workers. The new Manchester facility is approximately 50% larger than the current Deeside operation and has capacity for up to 250 employees, allowing for future expansion.

Convatec's investment comes as part of a broader $1 billion worldwide R&D commitment, with the UK portion representing nearly half of this global initiative. The company, which generated $2.3 billion in revenue last year, typically allocates approximately 5% of its annual revenue to research and development. The relocation to Manchester positions Convatec to leverage the city's concentration of medical research institutions, including neighboring organizations such as the University of Manchester NHS Foundation Trust, biotech company QIAGEN, and MAC Clinical Research, strengthening its pipeline of new products addressing unmet needs in chronic care.

A long-awaited report into the practices of former NHS gynaecologist Daniel Hay has revealed significant failings in patient care that contributed to severe physical harm. The review, commissioned by the Gynaecology Review Steering Group and published on Wednesday, examined Mr. Hay's work at University Hospitals of Derby and Burton NHS Foundation Trust between 2015 and 2018. The investigation found that his risky practices and clinical shortcuts resulted in two women suffering severe physical harm and three experiencing moderate physical harm, with the report noting only "good fortune prevented further harm."

The panel reviewed 325 patients treated by Mr. Hay during the specified period, building upon an earlier assessment of 58 women conducted in 2019. The investigation identified numerous clinical deficiencies, including Mr. Hay's failure to take complete patient histories, omission of pre-operation scans, and inadequate documentation. His paperwork was described as "not of an acceptable standard," and he frequently failed to properly explain procedures or discuss risks and benefits with patients, leaving many feeling unsettled and uninformed about their treatment options.

Among the most concerning findings were instances where women underwent hysterectomies without proper consent or understanding of alternative treatments. The report indicated that some patients were made to feel that surgical removal of the womb was their "only option" when less invasive alternatives might have been available. This had profound consequences for women who dreamed of starting families, with the report noting the procedures "adversely affected" their mental health, relationships, and employment.

Following the report's publication, the NHS trust issued a formal apology, expressing being "truly sorry" to the women who received care "below the standards expected." The investigation has prompted recommendations to expand the review to include cases from 2012 to 2015, focusing on major and intermediate gynaecology surgeries. A criminal investigation into Mr. Hay's conduct remains ongoing as the healthcare system confronts the systemic failures that allowed these practices to continue unchecked for years.